Potomac Doo

Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy RADNOR, Pa., June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has added Dr. Dennis McBride to its Board of Directors. Dr. McBride brings deep experience in Neuroscience, Medical and Information Technology and digital therapeutics to the Company. "I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company." "I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies," commented Dr. McBride. "I look forward to using my experience to help advance its strategy and further the development of NRx's impressive pipeline of CNS products and leading its initiative in digital therapeutics." Dr. Dennis McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development both within the federal government and in the private sector, three of which are now multi-billion-dollar enterprises. He has formative experience in CNS-focused digital therapeutics, having participated with NRx founders in developing now military-proven digital therapeutic technology for reduction of stress and depression. He was instrumental to the founding of InQTel and other private sector-focused initiatives. Dr. McBride dedicated his Navy career to Aerospace Medicine and ergonomics, during which he served in leadership roles at six nationally-prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated Navy Captain, he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. He then joined the National Defense University as a Professor to lead the Center for Technology and National Security Policy, completing his term as a Senior Executive-4 (Civilian equivalent to Vice Admiral). Most recently, he served a tour of duty in the Office of the Secretary of Defense. Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes the University of Georgia, Naval Aerospace Medical Institute, the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology and four master's degrees. About NRx Pharmaceuticals NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. ( ) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. Company Codes: NASDAQ-NMS:NRXP

Dublin, March 09, 2021 (GLOBE NEWSWIRE) -- The "Pest Control Service Market Size, Share & Trends Analysis Report by Application (Residential, Commercial), by End Use (Insect, Termite), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering. The global pest control service market size is anticipated to reach USD 28.1 billion by 2027, expanding at a CAGR of 4.5% from 2020 to 2027. Changing climate and a rise in temperature are acting as major catalysts for the rising demand for pest control services. Other factors such as increasing commercial and residential projects and intolerance for pests are fueling the market growth. Moreover, the increasing popularity of the usage of biocides is supporting market growth. Factors such as environmental friendly nature and replacement for traditional pesticides are increasing the product demand. For instance, Rentokil has registered CO2 for use in the control of rodents under EU biocidal regulations. The company is continuing to work in the areas of insect and rodent control. Companies in the market are focusing on strategies, such as mergers and acquisitions, in order to gain market share and increase their service footprint. For instance, as per The Potomac Company, in 2018, Rentokil, ServiceMaster, and Rollins have spent USD 359, 254, and 77 million, respectively on pest control acquisition. In 2019, Rentokil Initial PLC had carried out 41 acquisitions in 23 countries. The company had acquired 30 pest control, 8 hygiene, and 3 Ambius businesses, generating annualized revenues in the year prior to purchase of USD 155.2 million (Euro 137 million). The company has carried acquisitions in Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Dutch Antilles, Finland, France, Greece, Indonesia, Malaysia, Peru, Poland, Spain, Tanzania, Thailand, the U.K., and the U.S. Moreover, the company has entered new markets of Jordan, Sri Lanka, and Uruguay. In terms of application, the commercial segment is estimated to expand at the fastest CAGR from 2020 to 2027. The growing commercial sector, coupled with strict rules and regulations, is acting as a major factor for the segment growth. Moreover, businesses have a multiyear contract with the service providers, leading to continuous revenue generation for the contract holding companies. The insect segment dominated the market with a revenue-based share of 42.0% in 2019. As per a research conducted by the National Pest Management Association (NPMA), in 2018, 97% of the pest professionals have treated bed bugs, 69% of them said that the overall bed bug service was effective, and 66% said that the demand for these services is increasing. Moreover, 89% of pest professionals encountered bed bugs in apartments/condominiums, 68% in hotels/motels, 59% in nursing homes, 46% in office buildings, 45% in college dorms, and 36% in hospitals. North America dominated the market with a revenue-based share of 48.3% in 2019. As per a report published by Rentokil, in 2018, 29% of all Americans have, at some point experienced a rodent pest issue, 35% in the Northeast. Moreover, 80% of U.S. hotels and motels reported some presence of bed bugs in the past year. Yellow fever mosquito is now found in 23 U.S. states - West Nile, Dengue, and Chikungunya viruses are now present in the U.S. Pest Control Service Market Report Highlights The commercial application segment is expected to witness the fastest growth from 2020 to 2027. The insect end-use segment was valued at USD 8.3 billion in 2019. Asia Pacific is expected to witness the fastest growth over the forecast period with a revenue-based CAGR of 5.3% from 2020 to 2027. Key Topics Covered: Chapter 1. Methodology and Scope Chapter 2. Executive Summary Chapter 3. Pest Control Service Market Variables, Trends & Scope 3.1. Market Introduction 3.2. Penetration & Growth Prospect Mapping 3.3. Industry Value Chain Analysis 3.3.1. Sales/Retail Channel Analysis 3.3.2. Profit Margin Analysis 3.4. Market Dynamics 3.4.1. Market Driver Analysis 3.4.2. Market Restraint Analysis 3.4.3. Industry Challenges 3.4.4. Industry Opportunities 3.5. Business Environment Analysis 3.5.1. Industry Analysis-Porter's 3.6. Roadmap of Pest Control Service Market 3.7. Market Entry Strategies Chapter 4. Consumer Behaviour Analysis 4.1. Consumer Trends and Preferences 4.2. Factors Affecting Buying Decision 4.3. Consumer Application Adoption 4.4. Observations & Recommendations Chapter 5. Pest Control Service Market: Application Estimates & Trend Analysis 5.1. Application Movement Analysis & Market Share, 2019 & 2027 5.2. Residential 5.3. Commercial Chapter 6. Pest Control Service Market: End Use Estimates & Trend Analysis 6.1. End Use Movement Analysis & Market Share, 2019 & 2027 6.2. Insect 6.3. Rodents 6.4. Termite 6.5. Mosquito 6.6. Others Chapter 7. Pest Control Service Market: Regional Estimates & Trend Analysis 7.1. Regional Movement Analysis & Market Share, 2019 & 2027 Chapter 8. Competitive Analysis 8.1. Key global players, recent developments & their impact on the industry 8.2. Key Company/Competition Categorization (Key innovators, Market leaders, Emerging players) 8.3. Vendor Landscape 8.3.1. Key company market share analysis, 2019 Chapter 9. Company Profiles 9.1. Company Overview 9.2. Financial Performance 9.3. Application Benchmarking 9.4. Strategic Initiatives Rentokil Initial PLC Rollins, Inc. ServiceMaster Global Holdings, Inc. Anticimex Group Arrow Exterminators Inc. Asante Inc. Dodson Pest Control Inc Ecolab Massey Services Inc. SANIX INC. For more information about this report visit CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900